Non-alcoholic fatty liver disease is the buildup of fat in the liver that is NOT caused by drinking too much alcohol. People who have it do not have a history of heavy drinking. NAFLD is closely related to being overweight.
Current Studies:
|
Fatty Liver Clinic
Enrolling: Yes
Principal Investigator: Dr. Niha Samala
Duration: 1 visit
Primary Outcomes measured: Adults with NAFLD.
|
Contact:
Brandon Wind
(317) 278-6222
bewind@iu.edu
|
|
Intercept 303 NASH
Enrolling: Yes
Principle Investigator: Dr. Raj Vuppalanchi
Duration: Up to 6 years.
Patient Population: Adults with Non-alcoholic Steatohepatitis, Fibrosis stage 2-3.
Drug(s): Obeticholic Acid tablet or Placebo
|
Contact:
Holly King
(317) 278-6200
hrking1@iu.edu
|
|
NAFLD Database 2 (NASH CRN)
Enrolling: Yes
Principle Investigator: Dr. Raj Vuppalanchi
Duration: 4 years
Patient Population: Adult patients with suspected or known non-alcoholic fatty liver
disease (NAFLD) or nonalcoholic steatohepatitis (NASH)-related cirrhosis of the liver.
|
Contact:
Jessie Vaughn
(317) 274-8427
jevaugh@iu.edu
|
|
HIV Fatty Liver
Enrolling: Yes
Principle Investigator: Dr. Samer Gawrieh
Duration: 1 visit
Patient Population: Adults with HIV and fatty liver.
|
Contact:
Montreca Robison
(317) 278-0408
mgrobiso@iu.edu
|
Closed Studies:
|
Gilead GS-US-384-1497 NASH Study
Enrolling: No
Duration: 36 weeks
Primary Outcomes measured: Adverse event profile:
Drug(s): GS-4997 alone or in combination with Simtuzumab
|
|
Galectin GT_026 The NASH-CX Trial
Enrolling: No
Duration: 67 weeks
Primary Outcomes measured: Evaluate the efficacy of GR MD 02 on reducing hepatic venous pressure gradient (HVPG) as a measure of portal pressure compared to placebo
Drug(s): GR-MD-02 in 2mg/kg body weight or 8 mg/kg body weight or placebo
|
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hyperension
Enrolling: No
Duration: 32 weeks; screening period of 6 weeks, double-blind treatment period of 24 weeks, follow-up period of 2 weeks
Primary Outcomes measured:
Drug(s): Emricasan tablet - 5mg, 25mg, 50mg or placebo
|
|
Fibroscan with CAP
Enrolling: No
Duration: 1 visit
|
|
Bristom-Myers Squibb NASH Study
Enrolling: No
Duration: 1 year; 16 weeks on treatment
Primary Outcomes measured: Change in percent hepatic fat fraction (%) by Magnetic Resonance Imaging
Drug(s): BMS-986036, daily subcutaneous injection
|
|
NuSirt Non-alcoholic fatty liver disease
Enrolling: No
Duration: 18 weeks total
Primary Outcomes measured: Change in hepatic fat
Drug(s): Fixed-dose Leucine, Metformin, Sildenafil Cominations (NS-0200) or placebo, capsules twice a day
|